Stem-like Cancer Cells in Breast Tumorigenesis

乳腺肿瘤发生中的干细胞样癌细胞

基本信息

  • 批准号:
    7387336
  • 负责人:
  • 金额:
    $ 24.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-04-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The long-range goal of my research is to uncover the nature of the cancer stem cells, and to design therapeutic approaches that can specifically target these cells for the treatment of breast cancers. The objective of this application is to establish the expression pattern of NS and Ngp1 in breast cancer cells, determine the growth phenotype and gene expression profile of NS- and Ngp1-expressing cells, and provide experimental evidence that demonstrates the role of NS+ cells in breast tumorigenesis. The central hypothesis is that NS and Ngp1 are preferentially expressed by the stem-like cells in breast tumors, and that these cells are responsible for the rapid growth, drug resistance, and high metastasis of malignant breast cancers. The rationale is that cancer stem cells, which are responsible for the high growth rate and drug resistance of malignant breast cancers, share common molecules such as NS and Ngp1 with somatic stem cells to drive the self-renewing machinery. Therefore, eliminating NS-expressing breast cancer cells will inhibit tumor initiation and progression. To accomplish the overall objective of this proposal, three specific aims will be pursued. The first aim is to establish the expression pattern of NS and Ngp1 in normal breast tissues and breast cancer cells. The second aim is to determine the cellular and molecular properties of those NS- and Ngp1-expressing cells by genetically marking these cells with living color proteins and purifying them by flow cytometry. The third aim is to determine the role of NS+ cells in the development, progression, and recurrence of breast tumors by evaluating the consequences of their elimination. An inducible cell ablation system will be employed to target the NS+ cells in transgenic animals. These results will provide the much-needed justification for the use of stem cell-targeting therapy in cancer treatment, and valuable information for developing new pharmacological and genetic therapies that can specifically target these cancer stem cells in order to cure advanced breast carcinomas.
描述(由申请人提供):我研究的长期目标是揭示癌症干细胞的性质,并设计可以特异性靶向这些细胞治疗乳腺癌的治疗方法。 本申请的目的是建立NS和Ngp 1在乳腺癌细胞中的表达模式,确定NS-和Ngp 1表达细胞的生长表型和基因表达谱,并提供证明NS+细胞在乳腺肿瘤发生中的作用的实验证据。 核心假设是NS和Ngp 1优先由乳腺肿瘤中的干细胞样细胞表达,并且这些细胞负责恶性乳腺癌的快速生长、耐药性和高转移。 其基本原理是,癌症干细胞是恶性乳腺癌的高生长率和耐药性的原因,它们与体干细胞共享共同的分子,如NS和Ngp 1,以驱动自我更新机制。 因此,消除表达NS的乳腺癌细胞将抑制肿瘤的发生和进展。 为实现本建议的总体目标,将追求三个具体目标。 第一个目的是建立NS和Ngp 1在正常乳腺组织和乳腺癌细胞中的表达模式。 第二个目的是确定这些NS-和Ngp 1-表达细胞的细胞和分子特性的遗传标记这些细胞与活的颜色蛋白和纯化它们通过流式细胞术。 第三个目的是通过评估NS+细胞消除的后果来确定NS+细胞在乳腺肿瘤的发展、进展和复发中的作用。 将采用诱导型细胞消融系统来靶向转基因动物中的NS+细胞。 这些结果将为在癌症治疗中使用干细胞靶向治疗提供急需的理由,并为开发新的药理学和遗传疗法提供有价值的信息,这些疗法可以特异性靶向这些癌症干细胞,以治愈晚期乳腺癌。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT Y TSAI其他文献

ROBERT Y TSAI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT Y TSAI', 18)}}的其他基金

Discovery of New DNA Methylation Biomarkers for Predicting the Malignant Outcome of Low-Grade Oral Dysplasia
发现新的 DNA 甲基化生物标志物,用于预测低度口腔发育不良的恶性结果
  • 批准号:
    10641351
  • 财政年份:
    2023
  • 资助金额:
    $ 24.52万
  • 项目类别:
Aging Effect on Genome Maintenance during Hepatocyte Regeneration
衰老对肝细胞再生过程中基因组维持的影响
  • 批准号:
    9315681
  • 财政年份:
    2016
  • 资助金额:
    $ 24.52万
  • 项目类别:
Role of Nucleostemin in Conferring The Drug Resistance of Hepatocellular Carcinoma
Nucleostemin 在赋予肝细胞癌耐药性中的作用
  • 批准号:
    9023201
  • 财政年份:
    2015
  • 资助金额:
    $ 24.52万
  • 项目类别:
Role of Nucleostemin in Conferring The Drug Resistance of Hepatocellular Carcinoma
Nucleostemin 在赋予肝细胞癌耐药性中的作用
  • 批准号:
    9187447
  • 财政年份:
    2015
  • 资助金额:
    $ 24.52万
  • 项目类别:
Stem-like Cancer Cells in Breast Tumorigenesis
乳腺肿瘤发生中的干细胞样癌细胞
  • 批准号:
    7204234
  • 财政年份:
    2005
  • 资助金额:
    $ 24.52万
  • 项目类别:
Stem-like Cancer Cells in Breast Tumorigenesis
乳腺肿瘤发生中的干细胞样癌细胞
  • 批准号:
    7574482
  • 财政年份:
    2005
  • 资助金额:
    $ 24.52万
  • 项目类别:
Stem-like Cancer Cells in Breast Tumorigenesis
乳腺肿瘤发生中的干细胞样癌细胞
  • 批准号:
    7047943
  • 财政年份:
    2005
  • 资助金额:
    $ 24.52万
  • 项目类别:
Stem-like Cancer Cells in Breast Tumorigenesis
乳腺肿瘤发生中的干细胞样癌细胞
  • 批准号:
    6902213
  • 财政年份:
    2005
  • 资助金额:
    $ 24.52万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 24.52万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 24.52万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.52万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.52万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 24.52万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.52万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 24.52万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 24.52万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 24.52万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.52万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了